|
Progression of prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
<sup>18</sup>F-PSMA-1007 PET/CT could detect PC lesions in 60% of the patients of a mixed population, including also patients with very low PSA values.
|
31728588 |
2020 |
|
Progression of prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, 11βHSD2 activity, catalysing 11-ketotestosterone biosynthesis, was shown to be key in the production of prostate specific antigen and in the progression of prostate cancer to castration resistant prostate cancer.
|
30825506 |
2019 |
|
Progression of prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Physicians often diagnose the progression of prostate cancer using serum prostate-specific antigen (PSA).
|
27270339 |
2017 |
|
Progression of prostate cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Here we screened a library of 810 miRNA mimics to identify miRNAs that alter AR activity in complementary functional assays including protein lysate microarray (LMA) quantification of AR and PSA protein levels, AR transcriptional reporter activity, and AR-positive PCa cell viability.
|
27683042 |
2016 |
|
Progression of prostate cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Moreover, miR-224 down-regulation was significantly associated with advanced clinical stage (P = .027) and metastasis (P = .001), whereas APLN up-regulation more frequently occurred in PCa tissues with advanced pathologic stage (P = .003), metastasis (P < .001), and prostate-specific antigen failure (P = .001).
|
25532941 |
2015 |
|
Progression of prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
The overexpression of MYC was more frequently found in PCa tissues with positive metastasis (P = 0.02) and PSA failure (P = 0.02).
|
23377984 |
2013 |
|
Progression of prostate cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our results demonstrate that Q640X mutated AR may have an important regulatory role in mediating the PSMA and PSA genes expression during the progression of prostate cancer from androgen-dependence to androgen-independence.
|
23418075 |
2013 |
|
Progression of prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
To perform the rAd5 constructs, we selected a combination of prostate-specific antigen (PSA) and prostate stem cell antigen (PSCA) genes based on their restricted distribution within the prostate tissue and their association with the development and progression of prostate cancer.
|
21668311 |
2011 |
|
Progression of prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
PSA is a marker for the progression of prostate cancer, but its mechanistic role in the disease is unclear.
|
21056970 |
2011 |
|
Progression of prostate cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The main goal of present work was to detect the expression of prostate specific antigen (PSA) and prostate-specific membrane antigen (PSM) genes in the micrometastases by the RT-PCR to assess the progression of prostate cancer.
|
21156999 |
2010 |
|
Progression of prostate cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This indicates the role of mutant allele of ER and CYP17 in the development and progression of prostate cancer and rules out any increased risk with PSA polymorphism in the north Indian population.
|
18722876 |
2008 |
|
Progression of prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
The capacity of a pure mammalian lignan, enterolactone (ENL), to influence the proliferation of the LNCaP human prostate cancer cell line was investigated as a function of cell density, metabolic activity, expression and secretion of prostate specific antigen (PSA), cell cycle profile, and the expression of genes involved in development and progression of prostate cancer.
|
18398867 |
2008 |
|
Progression of prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
We observed inhibition of the expression and function of the AR by POH, through inhibition of androgen-induced cell growth and androgen-stimulated secretion of prostate-specific antigen and hK2, in human pCa cell line LNCaP.
|
16029925 |
2006 |
|
Progression of prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
The loss of E-cadherin and associated increase in vimentin are indicative of EMT and provides compelling evidence that hK4, in particular, and PSA have a functional role in the progression of prostate cancer through their promotion of tumour cell migration.
|
16172196 |
2005 |
|
Progression of prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
The serum level of prostate-specific antigen (PSA) is useful as a clinical marker for diagnosis and assessment of the progression of prostate cancer, and in evaluating the effectiveness of treatment.
|
15708372 |
2005 |
|
Progression of prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Since PSA is supposed to play an active role in the progression of prostate cancer, we applied a quantitative RT-PCR to measure the absolute levels of prostate-specific antigen (PSA) mRNA expression in benign and malignant prostatic tissue.
|
12705330 |
2003 |
|
Progression of prostate cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Here we demonstrate that alpha-tocopheryl succinate (VES) can suppress the expression of prostate-specific antigen (PSA), a marker for the progression of prostate cancer.
|
12032296 |
2002 |
|
Progression of prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results suggest that the novel polymorphisms identified in the PSA gene promoter may affect transcriptional activity of the PSA gene, and an excess of PSA production may enhance rapid progression of prostate cancer.
|
11299734 |
2001 |